Close Menu

This article has been updated with additional information from the FDA regarding the scope of the proposed premarket notification exemptions. 

NEW YORK (GenomeWeb) – The US Food and Drug Administration has identified more than 1,000 Class II devices that it plans to exempt from 510(k) premarket notification requirements, including a number of genomic analysis instruments.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.